Information  X 
Enter a valid email address

MaxCyteIncStk $0.01DI (MXCT)

Date Time Source Announcement
14 Nov 2019 7:00 am
RNS
Presentation at Jefferies Healthcare Conference
07 Nov 2019 7:00 am
RNS
MaxCyte to Present at BIO-Europe 2019
01 Nov 2019 1:04 pm
RNS
Result of AGM
24 Oct 2019 7:00 am
RNS
MaxCyte Advances Phase I Clinical Trial
23 Oct 2019 7:01 am
RNS
Presentations at Cell & Gene Therapy Congress
08 Oct 2019 7:00 am
RNS
Notification of AGM and Audit Declaration
07 Oct 2019 7:00 am
RNS
Editas Clinical and Commercial License Agreement
30 Sep 2019 7:00 am
RNS
Updates on CARMA Platform at Upcoming Meetings
18 Sep 2019 7:00 am
RNS
Results for the Six Months ended 30 June 2019
09 Sep 2019 7:00 am
RNS
Presentation at ICLE 2019
14 Aug 2019 7:00 am
RNS
Notice of Results
17 Jul 2019 7:00 am
RNS
Trading Update
11 Jul 2019 7:00 am
RNS
MaxCyte to Host Capital Markets Day Today
05 Jul 2019 4:42 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
19 Jun 2019 7:00 am
RNS
Annual Report
12 Jun 2019 7:00 am
RNS
Appointment of Joint Corporate Broker
29 May 2019 7:00 am
RNS
Save the Date: Capital Markets Day
08 May 2019 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Phase I Clinical Trial of MCY-M11 Progressed
01 May 2019 7:00 am
RNS
ASGCT Presentation on First CARMA Drug Candidate
24 Apr 2019 7:00 am
RNS
Final Results for Year Ended 31 December 2018
08 Apr 2019 7:00 am
RNS
Launch of ExPERTT Instrument Family
26 Mar 2019 7:00 am
RNS
Notice of Full Year Results
19 Mar 2019 5:05 pm
RNS
Director Dealings
05 Mar 2019 7:00 am
RNS
Grant of Options
01 Mar 2019 7:00 am
RNS
Clinical & Commercial Agreement with Kite
26 Feb 2019 5:32 pm
RNS
Result of Special Meeting and Issue of Equity
05 Feb 2019 4:32 pm
RNS
Results of Placing
  7:00 am
RNS
Proposed Placing to raise a minimum of �10 million
15 Jan 2019 7:00 am
RNS
Trading Update
19 Dec 2018 7:00 am
RNS
Change of Auditor
 
Headlines
Top categories

20-Nov-2019 10:00 AM

Broker Forecast - Berenberg issues a broker note on Vesuvius

Berenberg today upgrades its investment rating on Vesuvius (LON:VSVS) to buy (from hold) and cut its price target to 485p (from 520p). Story provided ...

Company finder

a d v e r t i s e m e n t